IL36RN and neoplasm: Given that the binding affinity of IL-36γ to the IL-36R is ~ 100–1000-fold greater than IL-36RN, the ability of exogenously administered IL-36γ to augment the anti-tumor immune response and suppress tumor growth, may be, in part, due to a reversal in suppression mediated by these checkpoint inhibitors.